Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391066 · ClinicalTrials.gov registry record · Phase 2
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 627
- Enrollment target
NCT00391066: Clinical Trial Phase 2 study, sponsored by Biogen.
NCT00391066 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 627 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (371% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00391066, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 627 participants
- Enrollment target
Study Summary
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.
Interventions
- DRUG FCR
- DRUG FCR + Lumiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Why NCT00391066 stopped before completion
NCT00391066 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (371% higher).
The record links to 0 conditions, and to 2 interventions - of which FCR is the first listed.
NCT00391066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00391066 about?
NCT00391066 is a clinical study titled "Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)". This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.
What is the current status of trial NCT00391066?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 627 participants. The study started on 2006-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00391066?
The interventions under investigation include: FCR (DRUG), FCR + Lumiliximab (DRUG).
Who is sponsoring clinical trial NCT00391066?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00391066's enrollment target sits among peer trials
627 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia